Table III.
Estimated prevalencea (using sampling and participation weights) of the longitudinal symptom subgroups in the source population by age and sex based on 4736 responders to 6-month follow-up questionnaire
| Characteristic | Weighted Prevalence in Row, % (95% Confidence Interval) | |||||
|---|---|---|---|---|---|---|
| Categories of Follow-up Status on 6-month Questionnaire | ||||||
| Persistent n = 558 | Non-persistent n = 585 | Recurrent n = 190 | Stable Past n = 1059 | Incident n = 83 | Never n = 2261 | |
| Age (years) at baseline | ||||||
| ≤ 40 | 3.3 (1.5–5.1) | 7.1 (4.1–10.1) | 1.2 (0.4–1.9) | 20.8 (15.0–26.6) | 0.5 (0.02–1.0) | 66.8 (60.3–73.2) |
| 40 to 49 | 5.4 (2.4–8.4) | 7.0 (4.2–9.9) | 2.6 (0.7–4.5) | 15.7 (10.5–20.9) | 0.8 (0.08–1.5) | 65.4 (58.6–72.1) |
| 50 to 59 | 8.0 (5.2–10.8) | 6.5 (4.1–8.9) | 1.6 (0.5–2.8) | 17.2 (13.2–21.2) | 0.9 (0.0–1.9) | 63.4 (58.1–68.6) |
| 60 to 69 | 4.2 (2.3–6.1) | 4.7 (2.8–6.7) | 2.4 (0.9–4.0) | 11.5 (8.2–14.7) | 1.1 (0.08–2.2) | 71.8 (67.0–76.6) |
| ≥ 70 | 2.6 (1.1–4.2) | 3.2 (1.6–4.8) | 1.7 (0.2––3.1) | 8.6 (5.6–11.6) | 2.0 (0.2–3.8) | 75.7 (70.8–80.5) |
| Sex | ||||||
| Female | 4.7 (3.5–6.0) | 6.4 (4.9–7.9) | 2.0 (1.2–2.9) | 15.2 (12.9–17.6) | 1.0 (0.3––1.7) | 67.1 (63.9–70.3) |
| Male | 4.8 (3.1–6.7) | 3.9 (2.9–4.8) | 1.6 (0.6–2.6) | 12.4 (9.6––15.2) | 1.4 (0.4–2.4) | 72.4 (69.1–76.7) |
| Overall | 4.8 (3.8–5.8) | 5.5 (4.5–6.5) | 1.9 (1.3–2.5) | 14.2 (12.4–16.1) | 1.1 (0.6–1.7) | 69.0 (66.5–71.4) |
a
Weighted on sampling proportions (based on electronic health record [EHR] selection groups and race/ethnicity) and participation rates at baseline and at six months; and accounted for stratified survey sampling; 230 persons whose status at follow-up could not be ascertained were excluded from the table.
Abbreviation: CRS = chronic rhinosinusitis